Melanotan II

Overview

Melanotan II (MT-II) is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (alpha-MSH). Originally developed at the University of Arizona in the early 1990s by a team led by Dr. Victor Hruby and Dr. Mac Hadley, MT-II was designed as a more potent and metabolically stable derivative of the naturally occurring melanocortin peptide alpha-MSH.

The peptide acts as a non-selective agonist at melanocortin receptors MC1R through MC5R, with particular affinity for MC1R, MC3R, MC4R, and MC5R subtypes. Its cyclic structure, achieved through a lactam bridge between the lysine and aspartic acid residues at positions 4 and 10, confers significantly enhanced resistance to enzymatic degradation compared to linear alpha-MSH analogues.

MT-II was initially investigated for its potential as a sunless tanning agent due to its ability to stimulate melanogenesis through MC1R activation. Subsequent research revealed additional pharmacological activities mediated through its interactions with multiple melanocortin receptor subtypes, including effects on sexual function, appetite regulation, and inflammatory modulation.

Mechanism of Action

Melanotan II exerts its biological effects primarily through activation of the melanocortin receptor family, a group of five G protein-coupled receptors (MC1R-MC5R) that signal predominantly through the cyclic adenosine monophosphate (cAMP) pathway via Gs protein coupling.

MC1R-Mediated Melanogenesis

Upon binding to MC1R on epidermal melanocytes, MT-II triggers adenylyl cyclase activation, elevating intracellular cAMP levels. This activates protein kinase A (PKA), which phosphorylates cAMP response element-binding protein (CREB). Phosphorylated CREB upregulates microphthalmia-associated transcription factor (MITF), the master regulator of melanogenesis. MITF in turn drives expression of key enzymes including tyrosinase, tyrosinase-related protein 1 (TRP-1), and dopachrome tautomerase (TRP-2), shifting melanin production toward eumelanin synthesis.

MC3R/MC4R Central Nervous System Effects

MT-II crosses the blood-brain barrier and activates hypothalamic MC3R and MC4R. Activation of MC4R in the paraventricular nucleus has been shown to mediate effects on erectile function through descending oxytocinergic pathways. This mechanism, distinct from peripheral vasodilatory approaches, involves central neural signaling via the spinal cord to autonomic sacral outflow pathways.

MC4R and Energy Homeostasis

The MC4R is a key integrator of energy balance in the hypothalamus. MT-II activation of MC4R on neurons expressing the anorexigenic pro-opiomelanocortin (POMC) system contributes to appetite suppression. This occurs through modulation of downstream signaling cascades involving brain-derived neurotrophic factor (BDNF) and the sympathetic nervous system.

Research Summary

Melanotan II has been the subject of numerous preclinical and clinical investigations spanning several decades. The body of published research provides insights into its pharmacological profile and potential applications.

Melanogenesis and Photoprotection

Dorr et al. (1996) conducted one of the earliest clinical studies, published in Archives of Dermatology, demonstrating that subcutaneous administration of MT-II produced significant increases in skin melanin density in human volunteers without UV exposure. A subsequent study by Barnetson et al. (2006), published in the Journal of Investigative Dermatology, confirmed that MT-II could induce eumelanin production and provide measurable photoprotection against UV-induced DNA damage in fair-skinned individuals. This describes a measured laboratory endpoint and should not be read as evidence that MT-II is a safe or appropriate means of tanning or sun protection, particularly in light of the pigmentary and melanocyte-related concerns described in the safety section below.

Sexual Function Research

Wessells et al. (1998) published in the Journal of Urology that MT-II induced penile erections in men with psychogenic erectile dysfunction. This discovery led to the development of bremelanotide (PT-141), a metabolite-derivative of MT-II, which was eventually approved by the FDA in 2019 for hypoactive sexual desire disorder in premenopausal women under the brand name Vyleesi.

Appetite and Body Composition

Fan et al. (1997) demonstrated in Nature that intracerebroventricular administration of MT-II dramatically reduced food intake in rodent models, establishing the melanocortin system as a critical pathway in energy homeostasis. Subsequent work by Greenfield et al. (2009), published in the New England Journal of Medicine, confirmed the relevance of the MC4R pathway to human obesity.

Anti-Inflammatory Properties

Getting et al. (2006) published findings in Arthritis & Rheumatism demonstrating that melanocortin peptides, including MT-II, possess anti-inflammatory properties through activation of MC3R on macrophages and other immune cells, reducing pro-inflammatory cytokine release including TNF-alpha and IL-6.

Dosing in Published Research

Melanotan II is a synthetic analog of melanocyte-stimulating hormone. It is not an approved medicine and has no labeled dose. It was examined in a small pilot Phase 1 study in which single subcutaneous doses of roughly 0.01 to 0.03 mg per kilogram of body weight were given, with about 0.025 mg per kilogram identified as a tolerated single dose for further study. Side effects such as nausea and fatigue were noted at the higher end. These figures describe what was administered in that specific small study.

Safety and Side Effects

Melanotan II is not an approved drug in any jurisdiction. It has no approved medical use, has not completed the safety evaluation required for approval, and is widely sold illegally as an unlicensed product; regulatory agencies including the FDA and the UK Medicines and Healthcare products Regulatory Agency have issued warnings against its sale and use. Material sold under this name is of uncertain identity, dose, and purity.

Because MT-II is a non-selective melanocortin receptor agonist that strongly stimulates melanocytes, darkening of existing moles and other pigmented lesions (nevi) has been reported. This raises a theoretical concern about melanocyte stimulation in people with pre-existing atypical nevi. No causal link to melanoma has been established in clinical data, but the absence of controlled long-term data is itself a limitation, and there are published dermatology case reports of new and changing melanocytic lesions in people using melanotan products. Anyone with numerous moles, atypical moles, or a personal or family history of skin cancer should regard this as a significant unresolved concern, and any new, changing, or atypical pigmented lesion warrants dermatological evaluation.

Commonly reported acute effects include nausea, which is often pronounced after dosing, facial flushing, decreased appetite, and spontaneous penile erections, the last following directly from the compound’s melanocortin activity. Prolonged erection (priapism) has been reported and is a medical emergency. Other reported effects include darkening of freckles and new freckle formation, and injection-site reactions. Long-term safety, including any effect on melanoma risk, has not been characterized in controlled human trials.

Current Research Status

Melanotan II is an investigational compound that was never approved for human use. Research interest in melanocortin pharmacology led instead to the selective MC4R agonist bremelanotide (PT-141), which was developed separately and is the only melanocortin peptide in this area to reach FDA approval. The research literature on MT-II itself is limited and largely dated, and the compound is not approved for tanning, sexual function, or any other use. It is distributed only through unregulated channels.

Frequently Asked Questions